{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:07:57Z","timestamp":1788736077978,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["16447"],"award-info":[{"award-number":["16447"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["09150161910033"],"award-info":[{"award-number":["09150161910033"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["19OK009"],"award-info":[{"award-number":["19OK009"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006020","name":"Center for Translational Molecular Medicine","doi-asserted-by":"publisher","award":["04I-201"],"award-info":[{"award-number":["04I-201"]}],"id":[{"id":"10.13039\/501100006020","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunomodulatory therapies that improve the outcome of sepsis are not available. We sought to determine whether treatment of critically ill patients with sepsis with low-dose erythromycin\u2014a macrolide antibiotic with broad immunomodulatory effects\u2014decreased mortality and ameliorated underlying disease pathophysiology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a target trial emulation, comparing patients with sepsis admitted to two intensive care units (ICU) in the Netherlands for at least 72\u00a0h, who were either exposed or not exposed during this period to treatment with low-dose erythromycin (up to 600\u00a0mg per day, administered as a prokinetic agent) but no other macrolides. We used two common propensity score methods (matching and inverse probability of treatment weighting) to deal with confounding by indication and subsequently used Cox regression models to estimate the treatment effect on the primary outcome of mortality rate up to day 90. Secondary clinical outcomes included change in SOFA, duration of mechanical ventilation and the incidence of ICU-acquired infections. We used linear mixed models to assess differences in 15 host response biomarkers reflective of key pathophysiological processes from admission to day 4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 235 patients started low-dose erythromycin treatment, 470 patients served as controls. Treatment started at a median of 38 [IQR 25\u201352] hours after ICU admission for a median of 5 [IQR 3\u20138] total doses in the first course. Matching and weighting resulted in populations well balanced for proposed confounders. We found no differences between patients treated with low-dose erythromycin and control subjects in mortality rate up to day 90: matching HR 0.89 (95% CI 0.64\u20131.24), weighting HR 0.95 (95% CI 0.66\u20131.36). There were no differences in secondary clinical outcomes. The change in host response biomarker levels from admission to day 4 was similar between erythromycin-treated and control subjects.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this target trial emulation in critically ill patients with sepsis, we could not demonstrate an effect of treatment with low-dose erythromycin on mortality, secondary clinical outcomes or host response biomarkers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-04016-x","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:02:39Z","timestamp":1653386559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation"],"prefix":"10.1186","volume":"26","author":[{"given":"Tom D. Y.","family":"Reijnders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel","family":"Peters-Sengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke A.","family":"van Vught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Uhel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf L.","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn M.","family":"Stuiver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the MARS consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso M.","family":"de Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieuwe D. J.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerie J.","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roosmarijn T. M.","family":"van Hooijdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R. A.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Straat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom D. Y.","family":"Reijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjitske S. R.","family":"van Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Pereverzeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie J.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mischa A.","family":"Huson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse A.","family":"Wiewel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M. C. Klein","family":"Klouwenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S. Y.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos F.","family":"Frencken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Koster-Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"van de Groep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Verboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"4016_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA J Am Med Assoc. 2016;315:801\u201310.","journal-title":"JAMA J Am Med Assoc"},{"key":"4016_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-2600(14)70061-X","volume":"2","author":"JL Vincent","year":"2014","unstructured":"Vincent JL, Marshall JC, \u00d1amendys-Silva SA, Fran\u00e7ois B, Martin-Loeches I, Lipman J, et al. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med. 2014;2:380\u20136.","journal-title":"Lancet Respir Med"},{"key":"4016_CR3","doi-asserted-by":"crossref","unstructured":"SepNet Critical Care Trials Group. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med. 2016;42:1980\u20139.","DOI":"10.1007\/s00134-016-4504-3"},{"key":"4016_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1208623","volume":"369","author":"DC Angus","year":"2013","unstructured":"Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840\u201351.","journal-title":"N Engl J Med"},{"key":"4016_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195\u2013203.","journal-title":"Trends Mol Med"},{"key":"4016_CR6","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.","journal-title":"Nat Rev Dis Primers."},{"key":"4016_CR7","first-page":"273","volume":"31","author":"T Ladopoulos","year":"2018","unstructured":"Ladopoulos T, Giannaki M, Alexopoulou C, Proklou A, Pediaditis E, Kondili E. Gastrointestinal dysmotility in critically ill patients. Ann Gastroenterol. 2018;31:273\u201381.","journal-title":"Ann Gastroenterol"},{"key":"4016_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/CMR.00078-09","volume":"23","author":"S Kanoh","year":"2010","unstructured":"Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590\u2013615.","journal-title":"Clin Microbiol Rev"},{"key":"4016_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","volume":"8","author":"TDY Reijnders","year":"2020","unstructured":"Reijnders TDY, Saris A, Schultz MJ, van der Poll T. Immunomodulation by macrolides: therapeutic potential for critical care. Lancet Respir Med. 2020;8:619\u201330.","journal-title":"Lancet Respir Med"},{"key":"4016_CR10","doi-asserted-by":"publisher","first-page":"e00752-18","DOI":"10.1128\/AAC.00752-18","volume":"62","author":"A Patel","year":"2018","unstructured":"Patel A, Joseph J, Periasamy H, Mokale S. Azithromycin in combination with ceftriaxone reduces systemic inflammation and provides survival benefit in murine model of polymicrobial sepsis. Antimicrob Agents Chemother. 2018;62:e00752-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"4016_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0182023","volume":"12","author":"K Upadhyay","year":"2017","unstructured":"Upadhyay K, Hiregoudar B, Meals E, English BK, Talati AJ. Combination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsis. PLoS ONE. 2017;12:1\u201314.","journal-title":"PLoS ONE"},{"key":"4016_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.imlet.2011.04.001","volume":"138","author":"J Tong","year":"2011","unstructured":"Tong J, Liu ZC, Wang DX. Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis. Immunol Lett. 2011;138:137\u201343.","journal-title":"Immunol Lett"},{"key":"4016_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1006955","volume":"14","author":"H Namkoong","year":"2018","unstructured":"Namkoong H, Ishii M, Fujii H, Yagi K, Asami T, Asakura T, et al. Clarithromycin expands CD11b+Gr-1+cells via the STAT3\/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. PLoS Pathog. 2018;14:1\u201330.","journal-title":"PLoS Pathog"},{"key":"4016_CR14","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1128\/AAC.01024-16","volume":"60","author":"D Yoshioka","year":"2016","unstructured":"Yoshioka D, Kajiwara C, Ishii Y, Umeki K, Hiramatsu K, Kadota J, et al. The efficacy of \u03b2-lactam plus macrolide combination therapy in a mouse model of lethal pneumococcal pneumonia. Antimicrob Agents Chemother. 2016;60:6146\u201354.","journal-title":"Antimicrob Agents Chemother."},{"key":"4016_CR15","first-page":"190","volume":"144","author":"MJ Sanz","year":"2005","unstructured":"Sanz MJ, Abu Nabah YN, Cerd\u00e1-Nicol\u00e1s M, O\u2019Connor JE, Issekutz AC, Cortijo J, et al. Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression. Br J Pharmacol Br J Pharmacol. 2005;144:190\u2013201.","journal-title":"Br J Pharmacol Br J Pharmacol"},{"key":"4016_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1164\/ajrccm.151.5.7735618","volume":"151","author":"J Tamaoki","year":"1995","unstructured":"Tamaoki J, Tagaya E, Yamawaki I, Sakai N, Nagai A, Konno K. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med. 1995;151:1582\u20138.","journal-title":"Am J Respir Crit Care Med."},{"key":"4016_CR17","doi-asserted-by":"crossref","unstructured":"Maekawa T, Tamura H, Domon H, Hiyoshi T, Isono T, Yonezawa D, et al. Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1. JCI Insight. 2020;5(15):e136706.","DOI":"10.1172\/jci.insight.136706"},{"key":"4016_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1086\/529439","volume":"46","author":"EJ Giamarellos-Bourboulis","year":"2008","unstructured":"Giamarellos-Bourboulis EJ, Pechere J-C, Routsi C, Plachouras D, Kollias S, Raftogiannis M, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46:1157\u201364.","journal-title":"Clin Infect Dis"},{"key":"4016_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/jac\/dkt475","volume":"69","author":"EJ Giamarellos-Bourboulis","year":"2014","unstructured":"Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, Tsangaris I, Koutelidakis I, Marioli A, et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother. 2014;69:1111\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4016_CR20","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.02974-15","volume":"60","author":"T Tsaganos","year":"2016","unstructured":"Tsaganos T, Raftogiannis M, Pratikaki M, Christodoulou S, Kotanidou A, Papadomichelakis E, et al. Clarithromycin leads to long-term survival and cost benefit in ventilator-associated pneumonia and sepsis. Antimicrob Agents Chemother. 2016;60:3640\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"4016_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jcrc.2015.12.010","volume":"32","author":"M Afshar","year":"2016","unstructured":"Afshar M, Foster CL, Layden JE, Burnham EL. Azithromycin use and outcomes in severe sepsis patients with and without pneumonia. J Crit Care. 2016;32:120\u20135.","journal-title":"J Crit Care"},{"key":"4016_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.00054108","volume":"33","author":"MI Restrepo","year":"2009","unstructured":"Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33:153\u20139.","journal-title":"Eur Respir J"},{"key":"4016_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/atm.2017.12.25","volume":"6","author":"FD Simonis","year":"2018","unstructured":"Simonis FD, de Iudicibus G, Cremer OL, Ong DSY, van der Poll T, Bos LD, et al. Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients. Ann Transl Med. 2018;6:24.","journal-title":"Ann Transl Med"},{"key":"4016_CR24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2016.2691","volume":"315","author":"LAV Van Vught","year":"2016","unstructured":"Van Vught LAV, Klouwenberg PMCK, Spitoni C, Scicluna BP, Wiewel MA, Horn J, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA J Am Med Assoc. 2016;315:1469\u201379.","journal-title":"JAMA J Am Med Assoc"},{"key":"4016_CR25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1164\/rccm.201502-0355OC","volume":"192","author":"BP Scicluna","year":"2015","unstructured":"Scicluna BP, Klein Klouwenberg PMC, van Vught LA, Wiewel MA, Ong DSY, Zwinderman AH, et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am J Respir Crit Care Med. 2015;192:826\u201335.","journal-title":"Am J Respir Crit Care Med."},{"key":"4016_CR26","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1007\/s00134-020-06119-x","volume":"46","author":"F Uhel","year":"2020","unstructured":"Uhel F, Peters-Sengers H, Falahi F, Scicluna BP, van Vught LA, Bonten MJ, et al. Mortality and host response aberrations associated with transient and persistent acute kidney injury in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 2020;46:1576\u201389.","journal-title":"Intensive Care Med."},{"key":"4016_CR27","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1097\/CCM.0b013e3182923712","volume":"41","author":"PMCK Klouwenberg","year":"2013","unstructured":"Klouwenberg PMCK, Ong DSY, Bos LDJ, De Beer FM, Van Hooijdonk RTM, Huson MA, et al. Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients. Crit Care Med. 2013;41:2373\u20138.","journal-title":"Crit Care Med"},{"key":"4016_CR28","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2016.2691","volume":"315","author":"LA van Vught","year":"2016","unstructured":"van Vught LA, Klein Klouwenberg PMC, Spitoni C, Scicluna BP, Wiewel MA, Horn J, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315:1469\u201379.","journal-title":"JAMA"},{"key":"4016_CR29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758\u201364.","journal-title":"Am J Epidemiol"},{"key":"4016_CR30","first-page":"4","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Online). 2016;355:4\u201310.","journal-title":"BMJ (Online)"},{"key":"4016_CR31","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","volume":"25","author":"BA Dickerman","year":"2019","unstructured":"Dickerman BA, Garc\u00eda-Alb\u00e9niz X, Logan RW, Denaxas S, Hern\u00e1n MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25:1601\u20136.","journal-title":"Nat Med"},{"key":"4016_CR32","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167:492\u20139.","journal-title":"Am J Epidemiol"},{"key":"4016_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jac\/dkh309","volume":"54","author":"MJ Schultz","year":"2004","unstructured":"Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and crystic fibrosis. J Antimicrob Chemother. 2004;54:21\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4016_CR34","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","volume":"157","author":"S Kudoh","year":"1998","unstructured":"Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829\u201332.","journal-title":"Am J Respir Crit Care Med."},{"key":"4016_CR35","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.2147\/COPD.S181246","volume":"13","author":"Y Cui","year":"2018","unstructured":"Cui Y, Luo L, Li C, Chen P, Chen Y. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3813\u201329.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"4016_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1164\/rccm.201606-1225OC","volume":"196","author":"LA Van Vught","year":"2017","unstructured":"Van Vught LA, Wiewel MA, Hoogendijk AJ, Frencken JF, Scicluna BP, Klouwenberg PMCK, et al. The host response in patients with sepsis developing intensive care unit-acquired secondary infections. Am J Respir Crit Care Med. 2017;196:458\u201370.","journal-title":"Am J Respir Crit Care Med"},{"key":"4016_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/01621459.1984.10477060","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR. From association to causation in observational studies: the role of tests of strongly ignorable treatment assignment. J Am Stat Assoc. 1984;79:41\u20138.","journal-title":"J Am Stat Assoc"},{"key":"4016_CR38","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u201358.","journal-title":"Stat Med"},{"key":"4016_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424.","journal-title":"Multivar Behav Res"},{"key":"4016_CR40","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1517\/14656566.2013.795948","volume":"14","author":"JE Stevens","year":"2013","unstructured":"Stevens JE, Jones KL, Rayner CK, Horowitz M. Pathophysiology and pharmacotherapy of gastroparesis: Current and future perspectives. Expert Opin Pharmacother. 2013;14:1171\u201386.","journal-title":"Expert Opin Pharmacother."},{"key":"4016_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/MCC.0000000000000581","volume":"25","author":"MP Plummer","year":"2019","unstructured":"Plummer MP, Reintam Blaser A, Deane AM. Gut dysmotility in the ICU: diagnosis and therapeutic options. Curr Opin Crit Care. 2019;25:138\u201344.","journal-title":"Curr Opin Crit Care"},{"key":"4016_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"MA Brookhart","year":"2006","unstructured":"Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, St\u00fcrmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149\u201356.","journal-title":"Am J Epidemiol"},{"key":"4016_CR43","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/01.CCM.0000215112.84523.F0","volume":"34","author":"JE Zimmerman","year":"2006","unstructured":"Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today\u2019s critically ill patients. Crit Care Med. 2006;34:1297\u2013310.","journal-title":"Crit Care Med"},{"key":"4016_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc7135","volume":"12","author":"A Reintam","year":"2008","unstructured":"Reintam A, Parm P, Kitus R, Starkopf J, Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study. Crit Care. 2008;12:1\u20138.","journal-title":"Crit Care"},{"key":"4016_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u201361.","journal-title":"Pharm Stat"},{"key":"4016_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Kim HJ, Lonjon G, Zhu Y. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16.","journal-title":"Ann Transl Med."},{"key":"4016_CR47","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35:5642\u201355.","journal-title":"Stat Med"},{"key":"4016_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ Van Der Weele","year":"2017","unstructured":"Van Der Weele TJ, Ding P. Sensitivity analysis in observational research: Introducing the E-Value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"4016_CR49","first-page":"545","volume":"37","author":"JP Joelsson","year":"2020","unstructured":"Joelsson JP, Myszor IT, Sigurdsson S, Lehmann F, Page CP, Gudmundsson GH, et al. Azithromycin has lung barrier protective effects in a cell model mimicking ventilator-induced lung injury. Altex. 2020;37:545\u201360.","journal-title":"Altex"},{"key":"4016_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1465-9921-14-52","volume":"14","author":"L Amado-Rodr\u00edguez","year":"2013","unstructured":"Amado-Rodr\u00edguez L, Gonz\u00e1lez-L\u00f3pez A, L\u00f3pez-Alonso I, Aguirre A, Astudillo A, Batalla-Sol\u00eds E, et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. Respir Res. 2013;14:1\u20139.","journal-title":"Respir Res"},{"key":"4016_CR51","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1128\/AAC.00457-13","volume":"57","author":"K Yamada","year":"2013","unstructured":"Yamada K, Yanagihara K, Kaku N, Harada Y, Migiyama Y, Nagaoka K, et al. Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:3883\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"4016_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrneph.2017.165","volume":"14","author":"F Venet","year":"2018","unstructured":"Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14:121\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"4016_CR53","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1440-1843.2012.02135.x","volume":"17","author":"S Hodge","year":"2012","unstructured":"Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophagesin chronic obstructive pulmonary disease subjects. Respirology. 2012;17:802\u20137.","journal-title":"Respirology"},{"key":"4016_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1902\/jop.2014.140183","volume":"86","author":"P-C Lai","year":"2015","unstructured":"Lai P-C, Schibler MR, Walters JD. Azithromycin enhances phagocytic killing of aggregatibacter actinomycetemcomitans Y4 by human neutrophils. J Periodontol. 2015;86:155\u201361.","journal-title":"J Periodontol"},{"key":"4016_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000320319","volume":"81","author":"J Altenburg","year":"2010","unstructured":"Altenburg J, De Graaff CS, Van Der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics\u2014Part 1: biological mechanisms. Respiration. 2010;81:67\u201374.","journal-title":"Respiration"},{"key":"4016_CR56","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1378\/chest.11-1908","volume":"141","author":"AJ Walkey","year":"2012","unstructured":"Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest. 2012;141:1153\u20139.","journal-title":"Chest."},{"key":"4016_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-016-2866-1","volume":"5","author":"K Kawamura","year":"2016","unstructured":"Kawamura K, Ichikado K, Takaki M, Sakata Y, Yasuda Y, Shingu N, et al. Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. Springerplus. 2016;5:1\u20137.","journal-title":"Springerplus"},{"key":"4016_CR58","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00134-019-05586-1","volume":"45","author":"S Pons","year":"2019","unstructured":"Pons S, Timsit J-F, Ruckly S, Schwebel C, Papazian L, Azoulay E, et al. Impact of macrolide therapy in critically ill patients with acute respiratory failure: a desirability of outcome ranking analysis to investigate the OUTCOMEREA database. Intensive Care Med. 2019;45:1043\u20135.","journal-title":"Intensive Care Med."},{"key":"4016_CR59","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwr301","volume":"175","author":"G Danaei","year":"2012","unstructured":"Danaei G, Tavakkoli M, Hern\u00e1n MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250\u201362.","journal-title":"Am J Epidemiol"},{"key":"4016_CR60","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/CCM.0000000000004842","volume":"49","author":"KM Demerle","year":"2021","unstructured":"Demerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis subclasses: a framework for development and interpretation. Crit Care Med. 2021;49:748\u201359.","journal-title":"Crit Care Med."},{"key":"4016_CR61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41581-019-0199-3","volume":"16","author":"NL Stanski","year":"2020","unstructured":"Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020;16:20\u201331.","journal-title":"Nat Rev Nephrol."},{"key":"4016_CR62","doi-asserted-by":"publisher","first-page":"1900824","DOI":"10.1183\/13993003.00824-2019","volume":"54","author":"R K\u00f6nig","year":"2019","unstructured":"K\u00f6nig R, Cao X, Oswald M, Forstner C, Rohde G, Rupp J, et al. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning. Eur Respir J. 2019;54:1900824.","journal-title":"Eur Respir J"},{"key":"4016_CR63","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s00134-012-2559-3","volume":"38","author":"C van Delden","year":"2012","unstructured":"van Delden C, K\u00f6hler T, Brunner-Ferber F, Fran\u00e7ois B, Carlet J, Pech\u00e8re JC. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 2012;38:1118\u201325.","journal-title":"Intensive Care Med"},{"key":"4016_CR64","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2014.7247","volume":"312","author":"EAN Oostdijk","year":"2014","unstructured":"Oostdijk EAN, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EHR, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in icus a randomized clinical trial. JAMA J Am Med Assoc. 2014;312:1429\u201337.","journal-title":"JAMA J Am Med Assoc"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04016-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T10:05:40Z","timestamp":1677146740000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4016"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04016-x","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients were included via an opt-out consent procedure approved by the institutional medical ethics committees of both participating hospitals (Amsterdam University Medical Center, location AMC, Amsterdam; University Medical Center Utrecht, Utrecht, IRB no. 10-056C).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}